In addition to blocking the cancer-intrinsic pathways that promote immune cells exclusion (such as Wnt-β-catenin), VEGF inhibitors or anti-angiogenesis TKIs could rebalance the immunosuppressive TME by facilitating T cell infiltration, down-regulating the immune checkpoints, decreasing the accumulation of immunosuppressive cells, as well as inducing tumor vascular normalization in HCC. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.